Finally, compared to patients with persistently low NT-proBNP levels, no significant difference in the primary outcome was observed in those who exhibited a postprocedural reduction in NT-proBNP (aHR 1.18; 95% CI 0.47–3.00), while those with postprocedural NT-proBNP elevation (aHR 2.25; 95% CI 1.00–5.05) and those with persistently high levels (aHR 2.32; 95% CI 1.25–4.31) had significantly greater risk (Figure 5), based on models adjusted for sex, BMI, anaemia, LVEF, COPD, dyslipidaemia, atrial fibrillation, and chronic kidney disease (Table 5). The gene discussed is NPPB; the disease is chronic kidney disease.